Literature DB >> 21384290

Educational level and cognitive impairment in patients with Parkinson disease.

Anna Kierzynka1, Radosław Kaźmierski, Wojciech Kozubski.   

Abstract

BACKGROUND AND
PURPOSE: Parkinson disease (PD) is a risk factor for dementia. In addition, specific cognitive deficits can occur in PD patients without dementia. A patient's level of education could have an influence on the development of cognitive impairment in PD. The aim of this study was to examine the relationship between the level of education and cognitive performance in non-demented patients with PD.
MATERIAL AND METHODS: Thirty-seven consecutive, nondemented PD patients and 40 healthy controls fulfilled the inclusion criteria and were enrolled in the case-control study. Each of the controls and PD patients were classified, for the purpose of this study, into one of three groups (low, intermediate, higher), categorized by the number of years of education. There were no differences in education and age between the controls and PD patients. All of the subjects were evaluated with a battery of neuropsychological tests: Mini-Mental State Examination, Trail Making Tests, Stroop Test, Mental Rotation Test, and Verbal Fluency Test.
RESULTS: Less (low and intermediate) education was correlated with poor results from tests. The comparison of all groups of PD patients and controls demonstrated that PD subjects received lower test scores, especially for the low and intermediate groups. However, no statistically significant difference was reached between educationally advanced PD patients and the appropriate control subjects.
CONCLUSIONS: As compared to the controls, most non-demented PD patients presented executive-type cognitive dysfunction. The higher educational level, however, was associated with a lower risk of cognitive deterioration. We conclude that higher education might have protective effects in cognitive decline in PD.

Entities:  

Mesh:

Year:  2011        PMID: 21384290     DOI: 10.1016/s0028-3843(14)60056-6

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  5 in total

1.  The influence of cognitive reserve on cognition in Parkinson's disease.

Authors:  Janneke Koerts; Lara Tucha; Klaus W Lange; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2012-12-02       Impact factor: 3.575

2.  Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module.

Authors:  Chase C Hansen; Joshua B Smith; Abdallah S R Mohamed; Collin F Mulcahy; Jeffrey S Wefel; Katherine A Hutcheson; Kelsey Chrane; Jack Phan; Steven J Frank; Adam S Garden; Blaine D Smith; Hillary Eichelberger; Carthal Anderson; Colton McCoy; Marina Horiates; Conner Patrick; Sarah Floris; Chloe French; Beth M Beadle; William H Morrison; Shirley Y Su; Carol M Lewis; Michael E Kupferman; Jason M Johnson; Heath D Skinner; Stephen Y Lai; Ehab Y Hanna; David I Rosenthal; Clifton D Fuller; G Brandon Gunn
Journal:  Head Neck       Date:  2017-08-01       Impact factor: 3.147

Review 3.  Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.

Authors:  Peter Manza; Matthew Amandola; Vivekanand Tatineni; Chiang-Shan R Li; Hoi-Chung Leung
Journal:  NPJ Parkinsons Dis       Date:  2017-07-07

4.  Retrograde Procedural Memory in Parkinson's Disease: A Cross-Sectional, Case-Control Study.

Authors:  Laure Pauly; Claire Pauly; Maxime Hansen; Valerie E Schröder; Armin Rauschenberger; Anja K Leist; Rejko Krüger
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  The long-term trend of Parkinson's disease incidence and mortality in China and a Bayesian projection from 2020 to 2030.

Authors:  Fangyao Chen; Shiyu Chen; Aima Si; Yaqi Luo; Weiwei Hu; Yuxiang Zhang; Jiaojiao Ma
Journal:  Front Aging Neurosci       Date:  2022-09-15       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.